Theralase Technologies Inc. V.TLT

RE:Best in class 2and 3 year data

[CancerSlayer]

enriquesuave wrote: so far we beat all competitors on 2 and 3 year data and by far.  J&J tar 200 is down to 4.7% at 3 years and we are aiming for 21.4% as per Kaplan Meyer projections so far..  This shows how all other treatments show rapidly declining CR rates once they stop treating.  We also beat 2 years data of recently approved combination treatment Anktiva/ BCG.  24%% vs 25.6% for us based on Kaplan Meyer projection.  Can the FDA give us AA or even full approval right away?

Yep...the K-M projection for 2-3 year data surpasses Keytruda's 1 year results!  The results will certainly speak for themselves.  

A BTD & a load of education/salesmanship need to happen before any shareholder-friendly deal imo.   I'm not sure Big Pharma has a clue about the true potential of our tech as they've been so heavily buried/weighted in favor of chemo & immunotherapy.  Perhaps Dr. Lbiati & our esteemed advisors on the MSAB can help spread the word if/when we have a BTD/AA in hand.  To maximize value in any Pharma deal, one not only needs to back up that value with science, but also with potential for better/broader PDT acceptance in the medical community...shared amongst colleagues & teaching/research hospitals, especially in the US, which holds over 30% of the nearly $5Bn global PDT market (& projected to be over $8Bn in 2033).

If/when we reach the NMIBC approval milestone with our unique PDT compound/approach, our ACT should have a good chance to replace a significant % of this market (i.e. replacing Photofrin, ALA, etc.).  Add in NMIBC, the many other potential indications & widened marketing/acceptance, those billions should grow exponentially. JMO..